Oral Anticoagulation, Not Aspirin, Should Be Prescribed
A 62-year-old woman with paroxysmal atrial fibrillation should receive oral anticoagulation (warfarin or a direct oral anticoagulant like apixaban, rivaroxaban, or dabigatran), not aspirin alone. Aspirin is ineffective for stroke prevention in AF and should not be used 1.
Risk Stratification Using CHA₂DS₂-VASc
Calculate her CHA₂DS₂-VASc score:
- Age 65-74 years: 1 point
- Female sex: 1 point
- Total score: 2 points
With a CHA₂DS₂-VASc score of 2, oral anticoagulation is strongly recommended 2, 3. The 2014 AHA/ACC/HRS guidelines explicitly state that patients with a score ≥2 should receive oral anticoagulation (Class I, Level of Evidence A) 2.
Why Not Aspirin?
The evidence is unequivocal that aspirin should not be considered an effective stroke prevention strategy in AF patients 1. A large observational study of 49,916 AF patients with a CHA₂DS₂-VASc score of 1 (beyond sex alone) demonstrated that warfarin provided superior net clinical benefit compared to aspirin or no treatment 1.
More recent evidence confirms that aspirin for primary prevention in AF patients on anticoagulation significantly increases major bleeding (5.74 vs 1.37 per 100 patient-years) without reducing ischemic events 4. The 2018 CHEST guidelines state there is no evidence supporting aspirin for stroke prevention in female AF patients with no additional risk factors 5.
Guideline Interpretation for Female Patients
European guidelines differentiate between males and females: Female sex alone (CHA₂DS₂-VASc score of 1 in a woman with no other risk factors) does not mandate anticoagulation 1. However, at age 62, this patient has an additional risk factor (age 65-74 years contributes 1 point), bringing her total to 2 points, which clearly indicates oral anticoagulation 5.
The 2018 CHEST guidelines recommend that stroke prevention should be offered to AF patients with ≥1 non-sex CHA₂DS₂-VASc stroke risk factor (score ≥1 in males or ≥2 in females) 5.
Oral Anticoagulation Options
Direct oral anticoagulants (DOACs) are preferred over warfarin in most patients due to lower bleeding risks 6:
- Apixaban
- Rivaroxaban
- Edoxaban
- Dabigatran
These reduce stroke risk by 60-80% compared to placebo 6. Warfarin (target INR 2.0-3.0) remains an option but requires regular INR monitoring 2, 3.
Common Pitfalls to Avoid
Do not prescribe aspirin alone - it is inferior to oral anticoagulation and provides inadequate stroke protection 1, 4
Do not misinterpret female sex as the sole indication - at age 62, she has age 65-74 as an additional risk factor, making her CHA₂DS₂-VASc score 2 1
Do not add aspirin to anticoagulation for primary prevention - this significantly increases bleeding risk without benefit 4
Assess renal function before initiating DOACs and reevaluate at least annually 2, 3
Apply the same anticoagulation strategy regardless of AF pattern (paroxysmal, persistent, or permanent) 2, 3, 7
Bleeding Risk Assessment
Perform bleeding risk assessment using validated tools, but bleeding risk should not preclude anticoagulation - rather, it should identify modifiable bleeding risk factors 5. The net clinical benefit of anticoagulation substantially outweighs the bleeding risk in patients with CHA₂DS₂-VASc ≥2 1.